{
    "symbol": "RNLX",
    "quarter": 2,
    "year": 2023,
    "date": "2023-03-30 12:20:03",
    "content": "  Examples of these statements include without limitation, the potential benefits, including economic savings of KidneyIntelX, the potential for KidneyIntelX to receive regulatory approval from the FDA, the commercial prospects for KidneyIntelX including whether KidneyIntelX will be successfully adopted by physicians and distributed and marketed, our expectations regarding reimbursement decisions and the ability of KidneyIntelX to curtail cost of chronic and end stage kidney disease, optimize care delivery, and improve patient outcomes, trends in our market and potential benefits of government policy change, the impact of COVID-19 and other world events on our business, our expectations for hiring, product development, strategic partnerships and collaborations, reimbursement decisions, clinical studies and regulatory submissions, our business strategies and future growth including plans, expectations, and opportunities for financing our operations, and revenue projections and guidance. Since our last quarterly report Renalytix has made several fundamental advances including completion of $20 million capital round with significant new institutional investors, reaching the next prime points for our results on the KidneyIntelX real world evidence study, expansion of insurance coverage for KidneyIntelX, the transition to a permanent, long-term commercial insurance payment model at Mount Sinai Health System, execution of a cooperative research and development agreement with the U.S. Veterans Health Administration, and further progress towards FDA de novo marketing authorization of KidneyIntelX."
}